Drug intelligence / Profile preview

GRNCHND-1

Development stage: Preclinical
Lead developer: Lineage Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

GRNCHND-1 is an investigational cell therapy consisting of chondrocytes derived from human embryonic stem cells (hESCs). Originally developed by Geron Corporation, the program was transferred to Asterias Biotherapeutics in 2013 as part of a broader portfolio of hESC-derived cellular assets. The therapy is designed to treat osteoarthritis by regenerating or repairing damaged articular cartilage within the joints. By delivering functional, stem cell-derived chondrocytes directly to the site of injury, the treatment aims to restore the structural integrity of the cartilage, potentially alleviating chronic pain and improving joint mobility. Following the acquisition of Asterias Biotherapeutics by BioTime (now Lineage Cell Therapeutics) in 2019, the development of GRNCHND-1 has been categorized as pending or inactive in public pipeline disclosures.

Other names: hESC-derived chondrocytes

Beyond the preview

Go deeper on GRNCHND-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRNCHND-1.

Explore the full profile